Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Disease × lortalamine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Recurrence 1 Prostatic Neoplasms 1 Neoplasms 1 Disease 1

Interventions

Blood Specimen Collection 9 Surveys and Questionnaires 6 Magnetic Resonance Spectroscopy 6 Dexamethasone 6 Cyclophosphamide 6 Prednisone 5 Mammography 5 Colonoscopy 5 Biopsy 5 Positron Emission Tomography Computed Tomography 4 Magnetic Resonance Imaging 4 Lenalidomide 4 Biopsy, Fine-Needle 4 pembrolizumab 3 Tomography, X-Ray Computed 3 Surgical Procedures, Operative 3 Melphalan 3 Liquid Biopsy 3 Interviews as Topic 3 Diagnostic Tests, Routine 3 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3 weifuchun 2 obinutuzumab 2 fluciclovine F-18 2 daratumumab 2 carfilzomib 2 Urination 2 Preoperative Exercise 2 Positron-Emission Tomography 2 Methods 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02615067 2019-04-10

proSPECT-AS

Molecular Insight Pharmaceuticals, Inc.

Phase 3 Completed

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡